News about "Gland Pharma"

Gland Pharma Secures USFDA Approval for Ready-to-Use Vasopressin Injection

The product is bioequivalent and therapeutically equivalent to the reference drug Vasostrict. Vasopressin is indicated for adults with vasodilatory shock who remain hypotensive despite adequate fluid resuscitation and catecholamine support.

Gland Pharma | 27/08/2025 | By Darshana

Gland Pharma Secures USFDA Approval for Norepinephrine Bitartrate in 5 Percent Dextrose Injection Bags

Gland Pharma Ltd. has received USFDA approval for its generic Norepinephrine Bitartrate in 5 percent Dextrose Injection, securing First-to-File status with 180 days of exclusivity in the US market.

Gland Pharma | 16/08/2025 | By Mrinmoy Dey

Gland Pharma Gets FDA Approval for Phytonadione Injectable Emulsion

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin KI1 Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.

Gland Pharma | 16/12/2024 | By Aishwarya |  258

Six Pharma Firms Plans to Build Green Pharma Units in Telangana

As per the MoUs, the MSN Group will establish a manufacturing unit and an R&D centre and Aurobindo Pharma and Laurus Labs will set up formulation units.

Gland Pharma | 25/11/2024 | By Aishwarya |  305

Gland Pharma Reports Revenue of INR 14,058 Million in Q2FY25

Gland Pharma has reported a consolidated revenue of INR 14,058 million for Q2 FY25, marking a 2 percent increase compared to INR 13,734 million in Q2 FY24.

Gland Pharma | 05/11/2024 | By Aishwarya |  564

Gland Pharma Welcomes Shyamakant Giri as New CEO

Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in Indian and multinational organizations across Asia, Africa, MENA & LATAM markets.

Gland Pharma | 21/10/2024 | By Aishwarya |  550

Gland Pharma Reports 16 Percent YoY Revenue Growth in Q1FY25

Gland Pharma has revealed its financial results for the first quarter of FY25, ending June 30, 2024.

Gland Pharma | 07/08/2024 | By Aishwarya |  481

Gland Pharma Gets Tentative Approval from USFDA for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma Ltd. has secured tentative approval from the United States Food and Drug Administration (USFDA) for Latanoprostene Bunod Ophthalmic Solution, 0.024 percent.

Gland Pharma | 24/07/2024 | By Aishwarya |  466

Gland Pharma Appoints New Executive Chairman and CEO

Gland Pharma Ltd. has announced that Srinivas Sadu has been appointed as Executive Chairman and CEO of the company.

Gland Pharma | 11/06/2024 | By Aishwarya |  567

Gland Pharma Reports Remarkable Q4FY24 and FY24 Financial Performance

Gland Pharma Ltd. has announced its financial results for the fourth quarter (Q4FY24) and full year (FY24) ended on Mar 31, 2024.

Gland Pharma | 23/05/2024 | By Aishwarya |  575